102 related articles for article (PubMed ID: 32247939)
1. Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.
Ibrahim TS; Sheha TA; Abo-Dya NE; AlAwadh MA; Alhakamy NA; Abdel-Samii ZK; Panda SS; Abuo-Rahma GEA; Mohamed MFA
Bioorg Chem; 2020 Jun; 99():103797. PubMed ID: 32247939
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.
Abdelkarim H; Neelarapu R; Madriaga A; Vaidya AS; Kastrati I; Karumudi B; Wang YT; Taha TY; Thatcher GRJ; Frasor J; Petukhov PA
ChemMedChem; 2017 Dec; 12(24):2030-2043. PubMed ID: 29080240
[TBL] [Abstract][Full Text] [Related]
3. Quinazoline-chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in-silico studies of potential anticancer activity against multiple myeloma.
Mansour MA; AboulMagd AM; Abbas SH; Abdel-Aziz M; Abdel-Rahman HM
Arch Pharm (Weinheim); 2024 May; 357(5):e2300626. PubMed ID: 38297894
[TBL] [Abstract][Full Text] [Related]
4. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
Zhao N; Yang F; Han L; Qu Y; Ge D; Zhang H
Molecules; 2020 Feb; 25(3):. PubMed ID: 32046013
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 1,10-phenanthroline-based hydroxamate derivative as dual histone deacetylases/ribonucleotide reductase inhibitor with antitumor activities.
Shetty MG; Pai P; Dey B; Satyamoorthy K; Shil S; Nayak UY; T A; Sundara BK
Daru; 2024 Jun; 32(1):263-278. PubMed ID: 38683491
[TBL] [Abstract][Full Text] [Related]
6. In-silico design of novel potential HDAC inhibitors from indazole derivatives targeting breast cancer through QSAR, molecular docking and pharmacokinetics studies.
Pandiyan S; Wang L
Comput Biol Chem; 2024 Jun; 110():108035. PubMed ID: 38460437
[TBL] [Abstract][Full Text] [Related]
7. Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
Liu Q; Zhang B; Wang Y; Wang X; Gou S
Eur J Med Chem; 2022 Feb; 229():114058. PubMed ID: 34954595
[TBL] [Abstract][Full Text] [Related]
8. Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
Raji I; Yadudu F; Janeira E; Fathi S; Szymczak L; Kornacki JR; Komatsu K; Li JD; Mrksich M; Oyelere AK
Bioorg Med Chem; 2017 Feb; 25(3):1202-1218. PubMed ID: 28057407
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and histone deacetylase inhibition study of novel 4-(2-aminoethyl) phenol derivatives.
Podili R; Mishra KMA; Akkewar AS; Kumar S; Rayala VVSPK; Kulhari U; Sahu BD; P R; Sethi KK
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23591. PubMed ID: 38037273
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
Sodji QH; Patil V; Kornacki JR; Mrksich M; Oyelere AK
J Med Chem; 2013 Dec; 56(24):9969-81. PubMed ID: 24304348
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Evaluation of New Urushiol Derivatives as Potent Class I Histone Deacetylase Inhibitors.
Zhou H; Qi Z; Liu D; Xue X; Wang C
Chembiochem; 2023 Sep; 24(18):e202300238. PubMed ID: 37366008
[TBL] [Abstract][Full Text] [Related]
12. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy.
Patel HK; Siklos MI; Abdelkarim H; Mendonca EL; Vaidya A; Petukhov PA; Thatcher GR
ChemMedChem; 2014 Mar; 9(3):602-13. PubMed ID: 23956109
[TBL] [Abstract][Full Text] [Related]
13. Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety.
Bui HTB; Nguyen PH; Pham QM; Tran HP; Tran Q; Jung H; Hong QV; Nguyen QC; Nguyen QP; Le HT; Yang SG
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408604
[TBL] [Abstract][Full Text] [Related]
14. Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors.
ElHady AK; Shih SP; Chen YC; Liu YC; Ahmed NS; Keeton AB; Piazza GA; Engel M; Abadi AH; Abdel-Halim M
Bioorg Chem; 2020 May; 98():103742. PubMed ID: 32199305
[TBL] [Abstract][Full Text] [Related]
15. Naturally occurring benzoic acid derivatives retard cancer cell growth by inhibiting histone deacetylases (HDAC).
Anantharaju PG; Reddy BD; Padukudru MA; Kumari Chitturi CM; Vimalambike MG; Madhunapantula SV
Cancer Biol Ther; 2017 Jul; 18(7):492-504. PubMed ID: 28506198
[TBL] [Abstract][Full Text] [Related]
16. New thiouracil derivatives as histone deacetylase inhibitors and apoptosis inducers: design, synthesis and anticancer evaluation.
Elbatrawy OR; El Deeb MA; Hagras M; Agili F; Hegazy M; El-Husseiny AA; Elkady MA; Eissa IH; El-Kalyoubi S
Future Med Chem; 2023 Jun; 15(12):1019-1035. PubMed ID: 37492951
[No Abstract] [Full Text] [Related]
17. Evaluation and molecular docking study of two flavonoids from Oroxylum indicum (L.) Kurz and their semi-synthetic derivatives as histone deacetylase inhibitors.
Somsakeesit LO; Senawong T; Senawong G; Kumboonma P; Samankul A; Namwan N; Yenjai C; Phaosiri C
J Nat Med; 2024 Jan; 78(1):236-245. PubMed ID: 37991632
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.
Montero A; Beierle JM; Olsen CA; Ghadiri MR
J Am Chem Soc; 2009 Mar; 131(8):3033-41. PubMed ID: 19239270
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel benzimidazole derivatives as potent HDACs inhibitors against leukemia with (Thio)Hydantoin as zinc-binding moiety: Design, synthesis, enzyme inhibition, and cellular mechanistic study.
Abdulwahab HG; Mansour RE; Farghaly TA; El-Sehrawi HM
Bioorg Chem; 2024 May; 146():107284. PubMed ID: 38493640
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking, synthesis, characteristics and preliminary cytotoxic study of new coumarin-sulfonamide derivatives as histone deacetylase inhibitors.
Alibeg AAA; Mohammed MH
Wiad Lek; 2024; 77(3):514-525. PubMed ID: 38691794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
